(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 2.84% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.81%.
Amgen's revenue in 2026 is $37,220,000,000.On average, 36 Wall Street analysts forecast AMGN's revenue for 2026 to be $20,805,753,962,700, with the lowest AMGN revenue forecast at $19,618,935,468,174, and the highest AMGN revenue forecast at $21,794,499,520,668. On average, 36 Wall Street analysts forecast AMGN's revenue for 2027 to be $21,325,493,030,562, with the lowest AMGN revenue forecast at $19,525,565,936,772, and the highest AMGN revenue forecast at $23,869,138,125,924.
In 2028, AMGN is forecast to generate $21,850,629,181,164 in revenue, with the lowest revenue forecast at $19,388,480,035,176 and the highest revenue forecast at $25,079,703,784,506.